Orin Pharmaceuticals

Orin Therapeutics is a clinical-stage biotechnology company focused on developing first-in-class small molecule therapeutics for the treatment of cancer and other serious diseases. The company's lead candidate, Orin-1001, is a potent and selective inhibitor of the IRE1α (Inositol-requiring enzyme 1 alpha) pathway, which plays a critical role in the unfolded protein response (UPR) and is implicated in various cancers, including breast cancer and prostate cancer. Orin Therapeutics leverages its deep understanding of endoplasmic reticulum (ER) stress and the UPR to target novel pathways that drive tumor growth and drug resistance. The company is currently advancing its pipeline through clinical trials, with a focus on addressing unmet medical needs in oncology. Orin-1001 has received FDA Fast Track designation for the treatment of metastatic breast cancer, highlighting its potential as a significant therapeutic advancement. The company maintains operations in both the United States and China, supported by a strong network of venture capital investors.